Personalized medicine in multiple sclerosis

A forum to discuss research on the origins of MS and its development.
Post Reply
User avatar
Family Elder
Posts: 1572
Joined: Wed Dec 02, 2009 3:00 pm

Personalized medicine in multiple sclerosis

Post by frodo » Thu Jul 05, 2018 1:12 am

Personalized medicine here means to divide the patients in subgroups so that the response to medication is optimal.

It seems that some hospitals are already doing a personalized diagnosis (for example ... rosis.html , ... e-centers/). Given the amount of compounds for MS that we have, that all of them have secondary effects and that not all of them work for all the patients, I think is something that could be worth trying.

Some reports:

Personalized medicine in multiple sclerosis

The therapeutic approach in multiple sclerosis (MS) requires a personalized medicine frame beyond the precision medicine concept, which is not currently implementable due to the lack of robust biomarkers and detailed understanding of MS pathogenesis. Personalized medicine demands a patient-focused approach, with disease taxonomy informed by characterization of pathophysiological processes. Important questions concerning MS taxonomy are: when does MS begin? When does the progressive phase begin? Is MS really two or three diseases? Does a therapeutic window truly exist? Newer evidence points to a disease spectrum and a therapeutic lag of several years for benefits to be observed from disease-modifying therapy. For personalized treatment, it is important to ascertain disease stage and any worsening of focal inflammatory lesions over time.

And also is interesting this other:

Personalized medicine in multiple sclerosis: hope or reality? ... 015-10-116

Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is used to classify active and non-active patients and treatment responders and non-responders. Although this classification works on a group level, individual patients often behave differently from the group. Therefore additional biomarkers are needed to provide better indicators for prognosis and treatment response. Basic and clinical research have discovered different promising targets. It is now essential to verify the utility and accuracy of these markers in large, prospectively sampled patient cohorts.

Post Reply
  • Similar Topics
    Last post

Return to “MS Etiology and Pathogenesis”